(S)-Promethazine

(S)-Promethazine

SCHEMBL2900853

C[C@@H](CN1c2ccccc2Sc2ccccc21)N(C)C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

HRH1

The experimentally established mechanism targets of (S)-Promethazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH1 known ✓ P35367 3/20 1.00
CYP2D6 P10635 7/20 1.00
CHRM2 P08172 6/20 1.00
HTR1A P08908 6/20 1.00
CHRM1 P11229 6/20 1.00
ADRA1A P35348 6/20 1.00
OPRM1 P35372 6/20 1.00
DRD3 P35462 6/20 1.00
KCNH2 Q12809 6/20 1.00
ADRA2A P08913 5/20 1.00
DRD1 P21728 5/20 1.00
LMNA P02545 4/20 1.00
ALDH1A1 P00352 4/20 1.00
SLC6A2 P23975 4/20 1.00
SLC6A4 P31645 4/20 1.00
PTGS1 P23219 4/20 1.00
CYP1A2 P05177 4/20 1.00
ALOX15 P16050 3/20 1.00
HSD17B10 Q99714 3/20 1.00
SLC22A1 O15245 3/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Promethazine SCHEMBL26777 1.00 CYP2D6 (1.00) CYP2D6CHRM2HTR1ACHRM1ADRA1A
Promethazine SCHEMBL4700 1.00 CYP2D6 (1.00) CYP2D6CHRM2HTR1ACHRM1ADRA1A
Promethazine SCHEMBL29372077 1.00 CYP2D6 (1.00) CYP2D6CHRM2HTR1ACHRM1ADRA1A
Promethazine SCHEMBL5425141 0.98 LMNA (1.00) CYP2D6CHRM2HTR1ACHRM1ADRA1A
Promethazine SCHEMBL27559626 0.98 LMNA (1.00) CYP2D6CHRM2HTR1ACHRM1ADRA1A
Promethazine SCHEMBL2962420 0.98 LMNA (1.00) CYP2D6CHRM2HTR1ACHRM1ADRA1A
Promethazine SCHEMBL41904 0.98 LMNA (1.00) CYP2D6CHRM2HTR1ACHRM1ADRA1A
Promethazine SCHEMBL5501515 0.98 LMNA (1.00) CYP2D6CHRM2HTR1ACHRM1ADRA1A
Promethazine SCHEMBL29390401 0.98 LMNA (1.00) CYP2D6CHRM2HTR1ACHRM1ADRA1A
Promethazine SCHEMBL717498 0.97 CYP2D6 (0.94) CYP2D6CHRM2HTR1ACHRM1ADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240226084-A9 HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS TECHFIELDS PHARMA CO., LTD. (CN) 2024-07-11 US claimed
US-20240131017-A1 HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS TECHFIELDS PHARMA CO., LTD. (CN) 2024-04-25 US claimed
US-20240115562-A1 HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS TECHFIELDS PHARMA CO., LTD. (CN) 2024-04-11 US claimed
EP-2849738-A1 HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS Techfields Pharma Co., Ltd. (CN) 2015-03-25 EP claimed
US-20150072961-A1 HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS PREMIER RESEARCH INTERNATIONAL, LLC 2015-03-12 US claimed
WO-2013170655-A1 HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS TECHFIELDS PHARMA CO., LTD. (CN) 2013-11-21 WO claimed
EP-4413979-A2 PHARMACEUTICAL COMPOSITIONS FOR ANESTHESIOLOGICAL APPLICATIONS Melt Pharmaceuticals, Inc. (US) 2024-08-14 EP disclosed
US-20240226084-A9 HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS TECHFIELDS PHARMA CO., LTD. (CN) 2024-07-11 US disclosed
EP-3310439-B1 PHARMACEUTICAL COMPOSITIONS FOR ANESTHESIOLOGICAL APPLICATIONS COMPRISING BENZODIAZEPINE AND KETAMINE MELT PHARMACEUTICALS INC (US) 2024-05-29 EP disclosed
US-20240131017-A1 HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS TECHFIELDS PHARMA CO., LTD. (CN) 2024-04-25 US disclosed
EP-4356912-A2 HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS Techfields Pharma Co., Ltd. (CN) 2024-04-24 EP disclosed
US-20240115562-A1 HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS TECHFIELDS PHARMA CO., LTD. (CN) 2024-04-11 US disclosed
US-11857545-B2 High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions TECHFIELDS PHARMA CO., LTD. (CN) 2024-01-02 US disclosed
WO-2021195176-A1 PROCESSES AND AGENTS FOR GLAUCOMA AUFBAU MEDICAL INNOVATIONS LIMITED (IE) 2021-09-30 WO disclosed
US-20190142818-A1 HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOISITON THEREOF FOR TREATMENT OF PULMONARY CONDITIONS TECHFIELDS PHARMA CO., LTD 2019-05-16 US disclosed
EP-2849738-A1 HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS Techfields Pharma Co., Ltd. (CN) 2015-03-25 EP disclosed
US-20150072961-A1 HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS PREMIER RESEARCH INTERNATIONAL, LLC 2015-03-12 US disclosed
US-20140350081-A1 INSECT G-COUPLED RECEPTORS USEFUL AS TARGETS FOR INSECTICIDES AND COMPOUNDS AND REAGENTS IDENTIFIED USING THE SAME US ARMY, SECRETARY OF THE ARMY 2014-11-27 US disclosed
WO-2013170655-A1 HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS TECHFIELDS PHARMA CO., LTD. (CN) 2013-11-21 WO disclosed
US-20100285087-A1 SINGLE PHENOTHIAZINE ENANTIOMERS AS AGENTS FOR THE PREVENTION OF BONE LOSS THE UNIVERSITY OF TEXAS (US) 2010-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240226084-A9 HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS HRH4, HCAR2, PAH HRH1 7/4885CYP2D6 153/4885CHRM2 618/4885
US-20140350081-A1 INSECT G-COUPLED RECEPTORS USEFUL AS TARGETS FOR INSECTICIDES AND COMPOUNDS AND REAGENTS IDENTIFIED USING THE SAME DDT, ADRA2C, MCHR1 HRH1 36/4885CYP2D6 648/4885CHRM2 704/4885
US-20240115562-A1 HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS HRH4, HCAR2, PAH HRH1 7/4885CYP2D6 153/4885CHRM2 618/4885
US-20150072961-A1 HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS HRH4, HCAR2, PAH HRH1 7/4885CYP2D6 153/4885CHRM2 618/4885
US-20100285087-A1 SINGLE PHENOTHIAZINE ENANTIOMERS AS AGENTS FOR THE PREVENTION OF BONE LOSS ALPL, ENY2, BMP2 HRH1 1458/4885CYP2D6 785/4885CHRM2 739/4885
US-20240131017-A1 HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS HRH4, HCAR2, PAH HRH1 7/4885CYP2D6 153/4885CHRM2 618/4885
US-11857545-B2 High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions HRH4, HCAR2, PAH HRH1 7/4885CYP2D6 153/4885CHRM2 618/4885
US-20190142818-A1 HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOISITON THEREOF FOR TREATMENT OF PULMONARY CONDITIONS CPA3, HCAR2, HRH4 HRH1 16/4885CYP2D6 159/4885CHRM2 864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.